Three-year landmark data are also available from the phase 3 coBRIM study (NCT01689519), which evaluated cobimetinib plus vemurafenib vs placebo plus vemurafenib in patients with advanced BRAF V600-mutant melanoma; reported 3-year overall survival rates were 37.4 and 31.5%, respectively.38 This evidence concerns the gene BRAF and melanoma.